secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001493152-23-007365
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic publishes study showing TGF-β2 predicts poor survival in DIPG; OT-101 protocol accepted by NIHR
--------------------------------------------------------------------------------

- Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).
- TGFβ1 and TGFβ3 isoforms are also predictive; OT-101 is the only TGFβ2 inhibitor in late clinical development.
- Clinical study protocol for OT-101 in pediatric brainstem cancer accepted onto UK NIHR portfolio.
- CEO states targeting TGFβ2 could rectify previous clinical failures such as bintrafusp alfa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/0001493152-23-007365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315223007365/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer